Oral Presentation Details
A Randomized Clinical Trial of Three Doses of a Long-Acting Oral Direct Factor Xa Inhibitor Betrixaban in Patients With Atrial Fibrillation (Presentation #3015-12)
Presenter: Dr. Michael D. Ezekowitz
Session: Late-Breaking Clinical Trials II: Cardiac Arrhythmias
Date: Monday, March 15, 8:51-9:03 a.m. ET
Location: Georgia World Congress Center, Murphy Ballroom
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All